l e t t e r S Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates 1 . However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes 2 . By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.
Breast cancer recurs at distant sites in a substantial number of women who receive adjuvant chemotherapy after surgical removal of the primary breast tumor 1 . De novo resistance mechanisms within tumor cells before treatment are key factors leading to the failure of chemotherapeutic drugs to prevent metastatic recurrence. Therefore, the discovery of the genomic alterations and genes contributing to de novo chemoresistance to specific drugs is a key goal 2 . Although a number of multidrug resistance genes have been discovered, their overexpression is often induced during drug treatment 3, 4 and the expression of these genes in tumors before treatment is not generally useful for initial guidance of drug selection. Gene signatures generated from responses of tumor cell lines to drugs are reported to predict drug response in patients [5] [6] [7] ; however, some researchers have found that cell line-derived signatures are not predictive of response in clinical cases 8 . Repeatedly observed genomic gains or losses have helped to identify genomic regions that may harbor genes contributing to malignant behavior and poor outcome [9] [10] [11] [12] . Which genomic regions harbor genes that may contribute to de novo resistance to therapy is currently unknown.
We analyzed gene expression profiles of 115 breast carcinomas from women diagnosed between 2000 and 2003 and treated according to current guidelines, including adjuvant chemotherapy if indicated. We performed predictive analysis of microarrays (PAM 13 ) and identified 114 probes, encoding 75 known genes, differentially expressed between cases with early distant metastatic recurrence and cases without distant recurrence (Supplementary Table 1 ). Fifteen percent of these probes, corresponding to 12 different genes, mapped to chromosome 8q22, the only chromosomal region with statistically significant enrichment (P < 2.1 × 10 −9 ) of probes associated with metastatic recurrence (Fig. 1a) . We applied an alternative gene selection method based on Cox proportional hazard regression 13, 14 , which also showed differential overexpression of these 8q22 genes in tumors with distant recurrence (data not shown). These genes included those encoding cyclin E2 (CCNE2) and metadherin (MTDH), which are reportedly associated with metastatic recurrence and poor prognosis of breast cancer 15, 16 . Coordinate overexpression of neighboring genes often reflects chromosomal amplification. Indeed, we observed 8q22 amplification by single nucleotide polymorphism (SNP) array analysis in 50 breast cancers (Supplementary Fig. 1 ), and expression of the 8q22 genes correlated with DNA copy number (Supplementary Table 1) .
We confirmed 8q22 amplification by DNA interphase fluorescence in situ hybridization (FISH) and found it in 21% of 85 breast cancers that could be scored by FISH (Fig. 1b,c) . The degree of copy gain l e t t e r S correlated with average expression of the 12 recurrence-associated 8q22 genes (8q gene expression index, 8qEI) ( Fig. 1d and Supplementary Table 1) . Kaplan-Meier analysis showed 8q22 amplification was associated with reduced metastasis-free survival in the entire cohort evaluated by FISH (Fig. 1e) , in the estrogen receptor-negative (ER − ) cases (Supplementary Fig. 2a ) and in the women who had received anthracycline-based adjuvant chemotherapy (Fig. 1f) . In multivariate analysis, amplification of 8q22 was a strong independent prognostic factor for breast cancer recurrence (Supplementary Table 2) .
We sought validation in a meta-analysis of six independent cohorts annotated with treatment and outcome 12, 14, [17] [18] [19] [20] . KaplanMeier analysis showed a significant difference in disease-free survival between 8qEI low-expression and high-expression groups in either chemotherapy-treated (Fig. 1g) or untreated individuals (Supplementary Fig. 2b ). These results indicate that 8q22 amplification promotes overexpression of 8q22 genes in tumor tissue, which is associated with poor prognosis in untreated cases and shorter disease-free survival despite adjuvant chemotherapy.
To determine whether 8q22 genes influence sensitivity to chemotherapy, we treated the breast cancer cell line BT549 harboring chromosome 8q22 amplification with siRNA specific for the 12 candidate genes (Supplementary Fig. 3 ) and screened for alteration of sensitivity to chemotherapeutic drugs (Fig. 2a) . Depletion of two genes in particular, YWHAZ and LAPTM4B, significantly increased the sensitivity to anthracyclines (Fig. 2a) . YWHAZ codes for a known antiapoptotic protein, 14-3-3ζ (refs. 21,22) . LAPTM4B encodes a recently described lysosomal protein called lysosomalassociated protein transmembrane 4B, about which little is known with regard to breast cancer. We examined 16 breast cancer cell lines and found a strong positive correlation between higher endogenous LAPTM4B mRNA level and higher half-maximal inhibitory concentration (IC 50 ) (relative resistance) to anthracyclines (P < 0.00034, l e t t e r S Supplementary Fig. 4a ) and a weaker or no correlation with IC 50 to cisplatin and paclitaxel (P = 0.008 and P = 0.4, respectively; data not shown). The expression of YWHAZ in cell lines also correlated with the IC 50 to doxorubicin ( Supplementary Fig. 4 ). Specific knockdown of LAPTM4B and YWHAZ in three breast cancer cell lines, MDA-MB-231 (MDA231), HCC38 and CAMA-1 (Fig. 2b) , increased sensitivity to the anthracyclines doxorubicin ( Fig. 2c) and daunorubicin (data not shown) but had a weaker or no effect on sensitivity to cisplatin and paclitaxel (Fig. 2c) . Knockdown of either LAPTM4B or YWHAZ considerably increased doxorubicin-induced apoptosis (Fig. 2d) . Induction of apoptosis was less apparent in response to cisplatin treatment (Fig. 2d) .
To investigate the mechanism of how these two genes were modulating sensitivity to anthracyclines, we tracked the intracellular localization of anthracyclines by following the autofluorescence of doxorubicin. LAPTM4B expression in cell lines correlated with both the IC 50 of doxorubicin (Fig. 3a) and the appearance of doxorubicin in the nucleus within 24 h (Fig. 3b) . Knockdown of LAPTM4B by siRNA in MDA-MB-231 cells resulted in a substantial increase in nuclear localization of doxorubicin, detectable within 12 h to 24 h of treatment, maximal at 24 h to 36 h (12 h after withdrawal of drug) and sustained at 48 h (Fig. 3c) . Knockdown of LAPTM4B in BT549 cells resulted in a similar increase in nuclear localization at 24 h (data not shown). The decreased distribution of doxorubicin into the nucleus is associated with less phosphorylation of H2A histone family, member X (phospho-H2AX) (Fig. 3c,d) , a marker of DNA damage response, and consistent with reduced doxorubicin-induced apoptosis and increased IC 50 (Fig. 2) . YWHAZ abundance correlated with the IC 50 of doxorubicin (Fig. 3a) , and knockdown of YWHAZ slightly increased the phospho-H2AX levels in drug-treated cells (Fig. 3d) . These results suggest that one mechanism of poorer outcome for women harboring breast cancers with 8q22 amplification is increased expression of LAPTM4B and interference with nuclear accumulation of anthracyclines. YWHAZ may affect drug sensitivity through inhibition of apoptosis, consistent with previous reports 21, 22 .
We introduced hemagglutinin (HA)-tagged full-length LAPTM4B and YWHAZ into partially transformed human mammary epithelial cells (HMECs) 23 . Expression of either exogenous LAPTM4B or exogenous YWHAZ increased the IC 50 of doxorubicin (270% increase, P < 0.002 or 394% increase, P = 0.0001, respectively) but had no significant effect on sensitivity to paclitaxel or cisplatin (Fig. 3e,f) . The LAPTM4B-induced decrease in drug sensitivity parallels and is consistent with delayed appearance of anthracycline in the nucleus of LAPTM4B-overexpressing HMECs (Fig. 3g) .
Kaplan-Meier analysis of women treated with adjuvant chemotherapy showed that the expression of YWHAZ and LAPTM4B Anti-HA β-actin 1 l e t t e r S above median level was associated with shorter disease-free survival (Supplementary Fig. 2c ). The association of higher expression levels of YWHAZ and LAPTM4B with poor outcome after adjuvant chemotherapy is consistent with either a prognostic effect or a role of these two genes in chemotherapy resistance.
Finally, we tested LAPTM4B and YWHAZ for their association with response to anthracyclines in a neoadjuvant (preoperative) treatment trial of epirubicin monotherapy and with response to cisplatin in a neoadjuvant trial of cisplatin monotherapy (Fig. 4) . We evaluated the average of LAPTM4B and YWHAZ expression levels from expression array data of pretreatment tumor biopsies for their association with pathologic complete response (pCR) to epirubicin. The twogene expression levels showed a coherent pattern with higher levels of expression associated with the absence of pCR (and the presence of residual disease) after epirubicin treatment (Fig. 4a,b) . We evaluated the capability of the two genes to predict pCR by measuring the area under receiver operator characteristic (ROC) curve 24, 25 (AUC), which showed that higher expression of the two genes is associated with the absence of pCR after anthracycline chemotherapy in the cohort of 118 breast tumors (AUC 0.315, P < 0.00058, Fig. 4d) . The association is more significant in 87 ER − tumors that were also negative for overexpression of v-erb-b2 erythroblastic leukemia viral oncogene homolog-2(HER2 − ) tumors (AUC 0.241, P < 0.000062, Fig. 4e ). When we analyzed the two genes separately, both genes were predictive of poor response in the whole cohort and in the ER − HER2 − subset, but only LAPTM4B level was predictive in the ER − HER2 + subset (Supplementary Table 3 ). In contrast, the expression of the two genes was not associated with treatment response to cisplatin monotherapy in a separate neoadjuvant clinical trial in tumors negative for ER, progesterone receptor (PR) and HER2 (ER − PR − HER2 − ) 26 (AUC 0.675, P > 0.3, Fig. 4c,f and Supplementary Table 3) . Although MTDH, one of the twelve 8q22 genes, has been reported to induce chemoresistance to a broad spectrum of drugs in experimental models 16 , its expression was not predictive for pCR in either the epirubicin or the cisplatin trial (data not shown). We analyzed a third single-agent neoadjuvant therapy trial of predominantly ER + tumors treated with docetaxel 27 and found that higher levels of expression of LAPTM4B and YWHAZ were not associated with an inferior clinical response to therapy (data not shown). These results support the notion that LAPTM4B and YWHAZ overexpression is associated preferentially with poor response to anthracyclines.
LAPTM4B is similar to its family member LAPTM4A, which promotes selective resistance to anthracyclines but not cisplatin in Saccharomyces cerevisiae 28 . Our results show that LAPTM4B acts on anthracycline trafficking by reducing drug entry into the nucleus and decreasing drug-induced DNA damage. Higher YWHAZ expression protects cells from drug-induced apoptosis. Because these genes reside in proximity on chromosome 8q, amplification produces coordinated upregulation of their various functions, together resulting in preferential resistance to anthracyclines. The results from the three clinical trials support this contention and suggest that clinical options for the treatment of primary breast cancers might depend upon the status of 8q22 amplification and overexpression of LAPTM4B and YWHAZ in tumors. Anthracyclines seem to be a reasonable treatment in tumors without 8q22 amplification, and alternatives might be selected for those whose cancers harbor amplification.
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ONLINe MeTHOdS
Cohort. We obtained primary breast tumors of 115 subjects from the US National Cancer Institute-Harvard Breast Specialized Program Of Research Excellence blood and tissue repository under protocols approved by the DF/HCC Institutional Review Board, with informed consent from subjects. We performed Affymetrix U133 plus 2 gene expression array analysis as previously described 29, 30 . We represented a subset of 85 tumors in tissue microarrays and used them for FISH analysis (see Supplementary Methods). We analyzed 50 of the cases by Affymetrix 10K SNP array as previously described 31, 32 . A portion of the SNP and gene expression data was reported previously [29] [30] [31] [32] . Clinical and pathologic characteristics for each sample in the cohort are provided in Supplementary Table 4. Neoadjuvant Clinical Trials. The neoadjuvant Trial of Principle for breast cancer was conducted in European hospitals and coordinated at the Institut Jules Bordet. This trial is registered on the clinical trials site of the US National Cancer Institute (http://clinicaltrials.gov/ct2/show/NCT00162812?term=N CT00162812&rank=1/). Single-agent epirubicin was given as neoadjuvant (preoperative) chemotherapy to 118 reportedly ER − cases. After central review, four of the cases were found to be ER + . Of the remaining 114 ER − cases, 87 cases were classified as HER2 − on the basis of low v-erb-b2 erythroblastic leukemia viral oncogene homolog-2 (ERBB2 or HER2) module score 33 . Pretreatment core biopsy of the primary breast tumor was performed for diagnosis and RNA isolation. At completion of chemotherapy, pathologic response was determined by microscopic examination of the excised tumor and nodes. pCR was defined by the absence of residual invasive breast carcinoma in the breast and axillary nodes. This study was approved by the medical ethics committee of Institute Jules Bordet, and all women gave written informed consent before study entry. Gene expression data of U133plus 2 were generated from RNA of pretreatment core biopsies.
The trial of single-agent cisplatin (APP Pharmaceuticals) as neoadjuvant chemotherapy was given to women with ER − PR − HER2 − breast cancer 26 . Gene expression array data from pretreatment biopsies was available for 24 cases 26 . Pathological response was determined by microscopy examination after chemotherapy as described above.
We performed ROC curve analysis to evaluate the mean level of combined LAPTM4B and YWHAZ expression, or the levels of each individual gene, for their capacity to predict pCR. We evaluated the association of ranked gene expression levels with pCR by determining the AUC estimated through the concordance index 34 ; the corresponding P values are from one-sided Wilcoxon's rank test 35 . The ROC curves are plotted for prediction of pCR, so a curve below the midline in the low-right area of the graph indicates the ranked gene expression is associated with the absence of pCR.
Statistical analysis of gene expression arrays. We classified Affymetrix U133plus2.0 array data from tumor samples of 115 cases into those with distant recurrence within 36 months of diagnosis or those without distant recurrence after at least 36 months of follow-up. The 115 arrays were logtransformed and normalized, and we removed invariable genes by filtering with dChip software (P value < 0.05). We determined differentially expressed genes by PAM 13 using the PAMR package implemented in R language (http:// cran.r-project.org/web/packages/pamr/index.html). PAMR implements the shrunken nearest centroid method 13 . We selected genes at a false discovery threshold that minimized a tenfold cross-validation and test errors near the shrinkage parameter ∆ = 2. The PAM score indicates the degree of statistical association for expression of each gene and metastatic recurrence. We used Cox proportional hazard regression analysis 13, 14 to discover differentially expressed genes associated with time to recurrence.
Statistical analysis in independent cohorts. We pooled six independent gene expression array data sets 12, 14, [17] [18] [19] [20] for analysis as previously described 36 . We calculated 8qEI as the mean expression value of the twelve 8q22 genes identified in PAM analysis, and we scored it in each of the six independent cohorts. We defined an 8qEI level higher than the median as 8qEI high and an 8qEI level lower than the median as 8qEI low. We performed the classification in six cohorts separately and then combined into one data sheet with 1,348 samples. Of these, 1,130 had annotation for treatment and follow-up, 361 received adjuvant chemotherapy with or without hormonal therapy and 725 received no adjuvant hormonal or chemotherapy. We constrained follow-up time to a maximum of 10 years with annotation for disease-free survival. We carried out Kaplan-Meier analyses with the survival package within the R statistical package. We derived P values with the Mantel-Cox log-rank test.
Additional methods. Detailed methodology is described in the Supplementary Methods.
Microarray data. Microarray data sets are deposited in the National Center for Biotechnology Information Gene Expression Omnibus database under the following accession numbers: gene expression data from the Dana-Farber/ Harvard Cancer Center (DF/HCC) cases, GSE19615; SNP array data from 50 of the DF/HCC cases, GSE19594; gene expression data from the neoadjuvant epirubicin 'Trial of Principle', GSE16446; gene expression data from the neoadjuvant cisplatin trial, GSE18864.
